B. Beverloo

发表

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.

E. Vellenga, G. Juliusson, M. Höglund, 2021, Blood advances.

pediatric patients with Down syndrome: an iBFM-SG study Cytogenetic features of acute lymphoblastic and myeloid leukemias in

B. Johansson, A. Teigler‐Schlegel, O. Haas, 2013 .

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

M. Kersten, D. Hose, H. Goldschmidt, 2008 .

Sequential analysis of chromosome aberrations in multiple myeloma during disease progression.

P. Sonneveld, K. Wu, B. Beverloo, 2007, Clinical lymphoma & myeloma.

Multiple myeloma diagnostics: the role of imaging, chromosome analysis and multiparameter flowcytometry

P. Sonneveld, R. Raymakers, M. Stevens-Kroef, 2011 .

Megalobastic anemia, infantile leukemia, and immunodeficiency caused by a novel homozygous mutation in the DHFR gene

M. Nelen, A. Wagner, H. Lango Allen, 2022, Blood advances.

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

M. Kersten, D. Hose, H. Goldschmidt, 2010 .

1 Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome – an iBFM-SG study OF ACUTE LEUKEMIA IN DOWN SYNDROME

B. Johansson, A. Teigler‐Schlegel, O. Haas, 2007 .

Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes

J. Tchinda, B. Burkhardt, A. Schulz, 2021, Nature Medicine.

Deletions at chromosome regions 7q11.23 and 7q36 in a patient with Williams syndrome.

H. Meijers-Heijboer, F. Visscher, E. van Drunen, 2001, American journal of medical genetics.

Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study.

B. Johansson, A. Teigler‐Schlegel, O. Haas, 2008, Blood.

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high‐dose chemotherapy in patients with multiple myeloma

P. Sonneveld, B. van der Holt, G. Verhoef, 2007, British journal of haematology.

Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

P. Sonneveld, V. V. D. van der Velden, R. Mina, 2022, Blood.

Dasatinib in Children and Adolescents with Relapsed or Refractory Leukemia: Interim Results of the CA180-018 Phase I Study from the ITCC Consortium.

R. Pieters, A. Baruchel, M. L. Boer, 2008 .